Clinical Trial Update: A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) [Phase 3]

View source ↗

Summary

Phase 3 trial of linaclotide 290 μg in irritable bowel syndrome with constipation has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• Linaclotide (linaclotide)

Snippet

Sponsor: Ironwood Pharmaceuticals, Inc. | Conditions: Irritable Bowel Syndrome Characterized by Constipation | Phase 3 | Status: COMPLETED | Results posted: 2020-11-16